Bristol Buys DuPont: Re-Enters Imaging Agents, Adds To HIV Line
Executive SummaryBristol-Myers Squibb will re-enter the radiopharmaceutical business via the acquisition of DuPont Pharma.
You may also be interested in...
In light of rumors that Bristol-Myers Squibb is looking to buy a major biopharma, DOTW evaluates the role deal-making has played in the company’s rebuilding since it implemented its “string-of-pearls” strategy in 2007. Plus updates on Celgene/Presage, Array/Global Blood Therapeutics, Targacept/AstraZeneca and more.